Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2600)	4/7/2003 1:05:48 PM
From: Savant	Read Replies (1) \| Respond to of 3576

As was pointed out in the CC, the circulating cells were expected to return to previous levels. It is a second check on the efficacy of the treatment. The length of time for the return was variable. The next trial will test a vaccination rate at double the rate of the first trial. Further trials will address more issues. There are other trials being conducted. This treatment shows promise for virtually all types of cancer. It is very encouraging that no side effects have been noted. They have enough cash to last two years at the current burn rate. With further very promising trials, they should have no problem raising more, with favorable terms. IMHO> S.